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Volume 59, Number 5 Letters to the Editor 1475the incidence of patients who experience asymptomatic troponin
elevations.
With respect to the particular levels of troponin that were
considered signiﬁcant in our study, this point deserves further clar-
iﬁcation. An acknowledged limitation of the Vascular Study Group
of New England (VSGNE) database is that speciﬁc levels of
troponin are not collected. Similarly, details relating to the assays
used and the upper reference limits used at the various institutions
that contribute data to the VSGNE are not captured. We agree
with Dr Sandoval and Dr Garcia that this information, if it had
been available, would potentially be useful in further understanding
the association between postoperative troponin elevation and long-
term survival. We believe that further study using precise troponin
value measurements that would allow for troponin threshold ana-
lyses and stratiﬁcation by relevant cut points is warranted.
Results of the Coronary Artery Revascularization Prophylaxis
(CARP)2 trial inﬂuence not only our practice but also our deci-
sion not to draw any conclusions in our study that would contra-
dict its ﬁndings. We do not suggest prophylactic coronary
revascularization as a ﬁrst-line approach to decrease postoperative
myocardial ischemia. Further studies, such as the currently
enrolling Coronary CT Angiography Vascular Events in Non-
cardiac Vascular Surgery Patients Cohort Evaluation (CTA-
VISION)3 trial, are better suited than ours to shed light on
whether there are “high-risk” anatomies that might beneﬁt
from coronary revascularization. Instead, we recommend periop-
erative medical optimization as a potential intervention, where
evidence-based guidelines are more clearly established.4
We are in complete agreement with Drs Sandoval and Garcia
that increased awareness of new consensus recommendations5 for
routine postoperative troponin testing in high-risk patients is
needed. Our ﬁnding that isolated troponin elevations after
vascular surgery are associated with reduced postoperative 5-year
survival suggests that these events deserve to be taken seriously.
Future study will more clearly reveal whether routine postopera-
tive troponin testing is a cost-effective way in which to improve
long-term clinical outcomes after vascular surgery.
Jessica P. Simons, MD, MPH
Andres Schanzer, MD
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University of Massachusetts Medical School
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clopidogrel is unnecessary in peripheral arterial
surgery”
We read with interest the recent article by Saadeh and Sfeir1
reporting the safety of maintaining perioperative clopidogrel in
patients undergoing peripheral arterial surgery. This supplements
similar ﬁndings from our report from the Vascular Study Group
of New England (VSGNE) demonstrating that patients can safely
undergo peripheral arterial operations while taking clopidogrel
without increased incidence of serious bleeding complications,
including bleeding requiring reoperation or increased transfusion
requirement.2
Interestingly, there is persistent variation in practice surround-
ing perioperative clopidogrel management among vascular sur-
geons. Hamish et al3 reported that 43% and 55% of surgeons
would preferentially stop clopidogrel before carotid endarterec-
tomy (CEA) for symptomatic patients and asymptomatic patients,
respectively. Furthermore, these authors noted that more than 49%
of surgeons would stop clopidogrel more than 7 days before sur-
gery, irrespective of symptom status. One can infer that these
biases reﬂect the ongoing presumption that clopidogrel is associ-
ated with increased serious bleeding complications at the time of
surgery. We also determined in another VSGNE-based study of
more than 4500 patients, which demonstrated that protamine
reduced bleeding complications after CEA, that there was no evi-
dence that clopidogrel was associated with major adverse bleeding
complications.4 Reoperation for bleeding after CEA occurred in
1.0% of patients taking clopidogrel versus 1.2% in patients not tak-
ing clopidogrel (P ¼ .67). Of note, almost all patients were
receiving antiplatelet therapy at the time of surgery (73% aspirin
only, 3% clopidogrel only, 13% aspirin and clopidogrel). Accord-
ingly, we strongly support Saadeh’s and Sfeir’s conclusion that clo-
pidogrel can be safely maintained perioperatively, which is
especially important for patients with strong indications for its
use, such as those with drug-eluting coronary stents or symptom-
atic carotid disease.
David H. Stone, MD
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Reply
Considering that dual antiplatelet therapy with aspirin and clo-
pidogrel now is so commonly prescribed to atherosclerotic pa-
tients, vascular surgeons worldwide are still facing the issue of
the optimal perioperative treatment of these patients on a regular
